GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Gross Profit

Peak Bio (Peak Bio) Gross Profit : $0.61 Mil (TTM As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio Gross Profit?

Peak Bio's gross profit for the three months ended in Jun. 2023 was $0.00 Mil. Peak Bio's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $0.61 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Peak Bio's gross profit for the three months ended in Jun. 2023 was $0.00 Mil. Peak Bio's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Peak Bio's Gross Margin % for the quarter that ended in Jun. 2023 was N/A%.

Peak Bio had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Peak Bio Gross Profit Historical Data

The historical data trend for Peak Bio's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peak Bio Gross Profit Chart

Peak Bio Annual Data
Trend Dec21 Dec22
Gross Profit
0.53 0.61

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Profit Get a 7-Day Free Trial - - 0.61 - -

Competitive Comparison of Peak Bio's Gross Profit

For the Biotechnology subindustry, Peak Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peak Bio's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peak Bio's Gross Profit distribution charts can be found below:

* The bar in red indicates where Peak Bio's Gross Profit falls into.



Peak Bio Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Peak Bio's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0.608 - 0
=0.61

Peak Bio's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.61 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Peak Bio's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Peak Bio  (OTCPK:PKBO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Peak Bio had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Peak Bio Gross Profit Related Terms

Thank you for viewing the detailed overview of Peak Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Peak Bio (Peak Bio) Business Description

Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019